Matching articles for "Uzedy"
In Brief: A New Indication for Uzedy
The Medical Letter on Drugs and Therapeutics • January 19, 2026; (Issue 1746)
Uzedy, an extended-release, subcutaneous (SC)
formulation of the second-generation antipsychotic
drug risperidone, was approved by the FDA in 2023 for
treatment of schizophrenia in adults. It has now...
Uzedy, an extended-release, subcutaneous (SC)
formulation of the second-generation antipsychotic
drug risperidone, was approved by the FDA in 2023 for
treatment of schizophrenia in adults. It has now been
approved for use as monotherapy or in combination
with lithium or valproate for maintenance treatment
of bipolar I disorder in adults. Extended-release,
intramuscular (IM) formulations of risperidone
(Risperdal Consta and Rykindo) are also approved for
treatment of bipolar I disorder (see Table 1).
In Brief: Three New Injectable Antipsychotic Drugs
The Medical Letter on Drugs and Therapeutics • December 25, 2023; (Issue 1692)
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the...
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the FDA
for treatment of schizophrenia in adults. Rykindo and
Abilify Asimtufii are also approved for maintenance
treatment of bipolar I disorder in adults. Other
extended-release injectable formulations of
risperidone and aripiprazole have been available in
the US for years (see Table 1).